These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3227498)

  • 41. Review of Canadian pharmacist involvement in adverse drug reaction reporting.
    Taras-Zasowski KM; Einarson TR
    Can J Hosp Pharm; 1989 Jun; 42(3):105-8, 133. PubMed ID: 10318271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 43. Monitoring adverse drug reactions in the postmarketing phase.
    Hoigné R; Hottinger S
    Pharm Acta Helv; 1988; 63(1):2-12. PubMed ID: 3283774
    [No Abstract]   [Full Text] [Related]  

  • 44. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods].
    Lagier G; Vincens M; Lefebure B; Frelon JH
    Therapie; 1983; 38(3):295-302. PubMed ID: 6612666
    [No Abstract]   [Full Text] [Related]  

  • 45. Should new drugs be avoided?
    Child Health Alert; 2002 Jun; 20():2. PubMed ID: 12096722
    [No Abstract]   [Full Text] [Related]  

  • 46. Drug-induced memory disorders.
    Prescrire Int; 2010 Feb; 19(105):29. PubMed ID: 20455342
    [No Abstract]   [Full Text] [Related]  

  • 47. Epidemiologic assessment of adverse drug effects.
    Stern RS
    Semin Dermatol; 1989 Sep; 8(3):136-40. PubMed ID: 2701270
    [No Abstract]   [Full Text] [Related]  

  • 48. [Regulatory guidelines and drug safety].
    Flury W
    Ther Umsch; 1993 Jan; 50(1):49-51. PubMed ID: 8378867
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Toward improved adverse event/suspected adverse drug reaction reporting.
    Gross R; Strom BL
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
    [No Abstract]   [Full Text] [Related]  

  • 50. Drug samples are meant for advertising.
    Thawani V
    Issues Med Ethics; 2001; 9(3):91. PubMed ID: 16334483
    [No Abstract]   [Full Text] [Related]  

  • 51. [Eighth French Drug Surveillance Seminar. Paris, 23-24 October 1986].
    Therapie; 1987; 42(4):331-410. PubMed ID: 3686465
    [No Abstract]   [Full Text] [Related]  

  • 52. [Seventh French Drug Surveillance Seminar. Caen, 21-22 November 1985].
    Therapie; 1986; 41(5):323-84. PubMed ID: 3810518
    [No Abstract]   [Full Text] [Related]  

  • 53. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Is imputation in drug surveillance reliable?].
    Girard M
    Therapie; 1984; 39(3):291-6. PubMed ID: 6463954
    [No Abstract]   [Full Text] [Related]  

  • 55. Responsibility for pharmaceutical company samples.
    Reti S
    N Z Med J; 2005 May; 118(1215):U1472. PubMed ID: 15915193
    [No Abstract]   [Full Text] [Related]  

  • 56. Postmarketing drug dosage changes.
    Peck CC
    Pharmacoepidemiol Drug Saf; 2003; 12(5):425-6. PubMed ID: 12899120
    [No Abstract]   [Full Text] [Related]  

  • 57. [6th French seminar on drug surveillance. Clermont-Ferrand, 22-23 November 1984].
    Therapie; 1985; 40(5):287-376. PubMed ID: 4095682
    [No Abstract]   [Full Text] [Related]  

  • 58. [Is establishment of causality in drug surveillance reliable?].
    Evreux JC
    Therapie; 1984; 39(4):437-8. PubMed ID: 6484888
    [No Abstract]   [Full Text] [Related]  

  • 59. [4-year experience in drug surveillance].
    Capellà D; Avila P; Cabeza L; Moreno V; Vidal X; Laporte JR
    Med Clin (Barc); 1988 Jun; 91(3):93-6. PubMed ID: 3172912
    [No Abstract]   [Full Text] [Related]  

  • 60. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
    Marsh DA; Hoar ME
    Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.